股票 › SBHMY
中国生物制药 SBHMY
美股市值排名 #1159
$14.62 +$0.45 (+3.15%)
休市 · Nov 8, 4:50 am ET
开盘$12.04
昨收$14.17
当日区间$12.04 – $12.04
成交量128
市值$14.50B
市盈率（TTM）38.5
股息率2.09%
SBHMY 相关新闻
匹配 SINO BIOPHARMACEUT 或代码 SBHMY 的头条新闻，按最新排序。
- Sino Biopharm (1177.HK): Significant Improvement in Profitability; Breakthrough in Out-licensing of Innovative Drugs 正面
- Sino Biopharm (01177.HK): Platform-based innovation combined with global expansion drives the realization of big pharma status, ushering in a second growth curve 正面
- Hong Kong Stocks in Motion | Sino Biopharm (01177) rises nearly 4%; subsidiary reaches strategic cooperation with STADA on biosimilars, securing an upfront payment of up to €53 million 正面
- Sino Biopharm (1177.HK): Profitability significantly improved; innovation transformation and global partnerships continue to deliver results
- Sino Biopharm (01177 HK): Innovative drug business grows rapidly; BD efforts are accelerating realization.
- Sino Biopharm (01177.HK) 2026 Interim Report Commentary: Dual-Drive from Innovative Products and BD, with AI Empowering the Entire Business Chain
- Sino Biopharm (1177.HK): AI Deeply Empowers the R&D System; Two-Way BD Accelerates Globalization
- Sino Biopharm (01177.HK): BD deal successfully closed, with the innovative pipeline accelerating its realization.
- Sino Biopharm (1177.HK): Profit Quality Significantly Improved; Innovative Pipeline Accelerating Realization 正面
- Major Bank Ratings | Daiwa: Raises Sino Biopharm’s Target Price to HK$7.2, Reiterates "Buy" Rating 正面
- Sino Biopharm (1177.HK): BD Deals Are Being Realized, and the Platform's Innovative Value Has Been Validated
- SINO BIOPHARM: COMPLETION OF SHARE TRANSACTION - ACQUISITION OF 100% EQUITY INTEREST IN HYGIEIA INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE
- SINO BIOPHARM: NEXT DAY DISCLOSURE RETURN
- SINO BIOPHARM: NEXT DAY DISCLOSURE RETURN
- SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
暂无评论——快来第一个聊聊 SBHMY。
登录后参与讨论。